top of page
The Professional Network for Healthcare Experts
Teva secures US commercialisation rights to two Samsung Bioepis immunology biosimilars in deal worth up to $420 million
Teva has secured US commercialisation rights to two FDA-approved Samsung Bioepis immunology biosimilars under an agreement worth up to $420 million, expanding its specialty biologics portfolio.
nuaxia
23 hours ago2 min read
Samsung Bioepis and Teva expand biosimilars partnership to up to six candidates
Samsung Bioepis and Teva have expanded their biosimilars collaboration to cover two named programmes and options for up to four additional candidates.
nuaxia
Oct 22 min read
Samsung Bioepis gains Japanese approval for intravenous Stelara biosimilar
Samsung Bioepis has received Japanese marketing approval for a 130mg intravenous formulation of its ustekinumab biosimilar referencing Stelara.
nuaxia
Sep 41 min read
bottom of page